Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability

“Taken together, the study provides novel insights into the regulation of MCL-1 expression by MCL1i, associated molecular changes and their implications.” Credit: 2023 Tantawy et al. “Taken together, the study provides novel insights into the regulation of MCL-1 expression by MCL1i, associated molecular changes and their implications.” BUFFALO, NY- June 28, 2023 – A new […]

Jun 28, 2023 - 20:00

Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability

“Taken together, the study provides novel insights into the regulation of MCL-1 expression by MCL1i, associated molecular changes and their implications.”

Credit: 2023 Tantawy et al.

“Taken together, the study provides novel insights into the regulation of MCL-1 expression by MCL1i, associated molecular changes and their implications.”

BUFFALO, NY- June 28, 2023 – A new editorial paper was published in Oncotarget’s Volume 14 on June 21, 2023, entitled, “Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability.”

The successful development of the BCL-2 inhibitor venetoclax, currently approved for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), encouraged the development of inhibitors that target other antiapoptotic proteins, particularly Myeloid Leukemia 1 (MCL-1). MCL-1 is among the top genes amplified in several cancers and is implicated in cancer progression, drug resistance and poor prognosis. It protects cancer cells from apoptosis and decreases their sensitivity to targeted agents or chemotherapeutics.

In this new editorial, researchers Shady I. Tantawy, Natalia Timofeeva, Ana Hernandez, Aloke Sarkar and Varsha Gandhi from The University of Texas MD Anderson Cancer Center discussed their recent investigation into the mechanism of MCL-1 inhibitor (MCL-1i)-induced Mcl-1 protein stability. The team explored underlying molecular mechanisms that contribute to MCL-1i-induced MCL-1 protein accumulation and its implications. Their study revealed a complex and multifaceted nature of MCL-1 protein accumulation in B-cell malignancies upon treatment with MCL-1i (AMG-176 and AZD5991).

“Collectively, these findings may have important implications for the development of next-generation MCL-1i with improved efficacy and safety profiles.”

Read the full paper: DOI: https://doi.org/10.18632/oncotarget.28440

Correspondence to: Aloke Sarkar, Varsha Gandhi

Emails: asarkar@mdanderson.org, vgandhi@mdanderson.org

Keywords: AMG-176, AZD5991, B-cell leukemia, MCL-1 inhibitor, MCL-1 protein

About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media: